On November 19, Palantir rose 3.08% in Pre-Market Trading, trading at $161.4337 per share, with turnover of $10.9277 million.
The move was associated with improving sentiment after the company’s England NHS Federated Data Platform contract was extended through 2029, alongside reported commercial order progress that reinforced expectations for durable medium-term demand.
Recent coverage indicated Palantir will continue on the NHS project through 2029, while additional commentary highlighted commercial traction including new customer wins and the fact that U.S. commercial revenue has surpassed U.S. government revenue. That combination appears to have outweighed a cautious options backdrop, where a $17.09 million in-the-money put structure and a much smaller $2.79 million long-dated call reflected mixed but near-term defensive positioning.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments